

18 August 2021

September 2021 Pharmaceutical Schedule Dispatch

Kia ora

This is an early notification of the changes to be announced in the **September 2021** Update to the Pharmaceutical Schedule.

The full Update will be available as a [PDF on our website](#). The changes will be published in the online Schedule around the 23rd of this month and are effective from next month.

For any questions about these listing changes or the Pharmaceutical Schedule in general, email us at enquiry@pharmac.govt.nz.

New listings

- Calcium carbonate (Calcium Sandoz Forte) tab eff 1.25g (500 mg elemental) – subsidy by endorsement, section 29 and wastage claimable (p'code 2617447)
- Cefaclor monohydrate (Ranbaxy-Cefaclor S29) cap 250 mg (p'code 2617501) and grams for oral liquid 125 mg per 5 ml (p'code 2617528) – section 29 and wastage claimable
- Clarithromycin (Klacid) tab 250 mg – maximum 56 tab per prescription, waived by Special Authority (p'code 2606038)
- Clarithromycin (Klacid) tab 500 mg – subsidy by endorsement, maximum 28 tab per prescription (p'code 2605295)
- Clomipramine hydrochloride (Clomipramine Teva) tab 10 mg (p'code 2611392) and 25 mg (p'code 2611406) – safety medicine; prescriber may determine dispensing frequency, section 29 and wastage claimable
- Diclofenac sodium (Voltaren SR) tab long-acting 75 mg (p'code 2140276)
- Dulaglutide (Trulicity) inj 1.5 mg per 0.5 ml prefilled pen – Special Authority – Retail pharmacy, will not be funded in combination with a SGLT-2 inhibitor (p'code 2617722)
- Fluorouracil (Fluorouracil Accord) inj 50 mg per ml, 20 ml vial (p'code 2618435) and 100 ml vial (p'code 2618427) – PCT only – Specialist
- Gabapentin (Nupentin) cap 100 mg (p'code 2422751), 300 mg (p'code 2422778) and 400 mg (p'code 2422786) – not subsidised in combination with subsidised pregabalin
- Icatibant (Firazyr) inj 10 mg per ml, 3 ml prefilled syringe – Special Authority – Retail Pharmacy (p'code 2617560)
- Lopinavir with ritonavir (Lopinavir/Ritonavir Mylan) tab 100 mg with ritonavir 25 mg (p'code 2613530), tab 200 mg with ritonavir 50 mg (p'code 2613549) – Special Authority – Retail pharmacy
- Melphalan (Alkeran S29) inj 50 mg – PCT only – Specialist, section 29 (p'code 2617404)

- Octreotide long-acting (Octreotide Depot Teva) inj depot 10 mg prefilled syringe (p'code 2615320), inj depot 20 mg prefilled syringe (p'code 2615339) and inj depot 30 mg prefilled syringe (p'code 2615347) – Special Authority – Retail Pharmacy
- Rivastigmine patch 4.6 mg per 24 hour (Rivastigmine Patch BMN 5) (p'code 2611570) and patch 9.5 mg per 24 hour (Rivastigmine Patch BMN 10) (p'code 2611589) – Special Authority – Retail pharmacy
- Selegiline hydrochloride (Eldepryl) tab 5 mg – subsidy by endorsement, section 29 and wastage claimable (p'code 2612410)
- Sumatriptan (Sumagran) tab 50 mg (p'code 2605848) and 100 mg (p'code 2605856)
- Taurine (Solgar) cap 500 mg – Special Authority – Retail pharmacy (p'code 2557797)
- Vinorelbine (Sagent) inj 10 mg per ml, 5 ml vial – PCT only – Specialist – section 29 (p'code 2618621)

Changes to restrictions, chemical names and presentations

- Cabergoline (Dostinex) tab 0.5 mg – amended restriction criteria
- Clarithromycin (Apo-Clarithromycin and Klacid) tab 250 mg and 500 mg – amended maximum number of tab per prescription
- Empagliflozin (Jardiance) tab 10 mg and 25 mg – amended Special Authority criteria and addition of rule not funded in combination with a funded GLP-1 agonist
- Empagliflozin with metformin (Jardiamet) tab 5 mg with 1,000 mg metformin hydrochloride, tab 5 mg with 500 mg metformin hydrochloride, tab 12.5 mg with 1,000 mg metformin hydrochloride, and tab 12.5 mg with 500 mg metformin hydrochloride – amended Special Authority criteria and addition of rule not funded in combination with a funded GLP-1 agonist
- Folic acid (Apo-Folic Acid) tab 0.8 mg – remove stat dispensing
- Furosemide [frusemide] (Apo-Furosemide) tab 40 mg – remove stat dispensing
- Metoprolol tartrate (Apo-Metoprolol) tab 50 mg and 100 mg – remove stat dispensing
- Mirtazapine (Noumed) tab 30 mg and 45 mg – remove section 29 and wastage claimable
- Nadolol (Apo-Nadolol) tab 40 mg and 80 mg – remove stat dispensing
- Octreotide long-acting (Octreotide Depot Teva and Sandostatin LAR) inj depot 10 mg, 20 mg and 30 mg prefilled syringe – amended chemical name, presentation description and Special Authority criteria
- Propranolol (Apo-Propranolol) tab 10 mg and 40 mg – remove stat dispensing
- Pyridoxine hydrochloride (Apo-Pyridoxine) tab 50 mg – remove stat dispensing
- Quinapril tab 5 mg (Arrow-Quinapril 5), tab 10 mg (Arrow-Quinapril 10), and tab 20 mg (Arrow-Quinapril 20) – reinstate stat dispensing
- Sumatriptan (Apo-Sumatriptan) tab 50 mg and 100 mg – Sole Supply ended 1 September 2021

Increased subsidy

Chemical	Presentation	Fully subsidised brands
Bezafibrate	Tab 200 mg Tab long-acting 400 mg	Bezalip Bezalip Retard
Citalopram hydrobromide	Tab 20 mg	PSM Citalopram
Domperidone	Tab 10 mg	Pharmacy Health
Latanoprost	Eye drops 0.005%, 2.5 ml OP	Teva
Mometasone furoate	Crn 0.1%, 15 g Crn 0.1%, 50 g Oint 0.1%, 15 g OP	Elocon Alcohol Free Elocon Alcohol Free Elocon
Pamidronate disodium	Inj 9 mg per ml, 10 ml vial	Pamisol
Pioglitazone	Tab 15 mg; 28 tab pack	Vexazone
Quinapril	Tab 10 mg Tab 20 mg	Arrow-Quinapril 10 Arrow-Quinapril 20
Zopiclone	Tab 7.5 mg	Zopiclone Actavis

Decreased subsidy

Chemical	Presentation	Fully subsidised brands	Partially subsidised brands
Fluorouracil	Inj 1 mg for ECP	Baxter	
Hydrocortisone butyrate	Lipocream 0.1%, 100 g OP	Locoid Lipocream	
Mometasone furoate	Lotn 0.1%, 30 ml OP	Elocon	
Quinapril	Tab 5 mg	Arrow-Quinapril 5	